Canada Hepatitis A Therapeutics Market Report 2023 to 2030

Canada Hepatitis A Therapeutics Market Analysis

$ 3999

The Canada Hepatitis A Therapeutics Market valued at $58.98 Mn in 2023, projected to reach $68.68 Mn by 2030 with a CAGR of 2.2%. Key industry drivers encompass increasing prevalence, inadequate personal hygiene and sanitation facilities, and government initiatives. Leading companies in this sector include GlaxoSmithKline (GSK) and Sanofi, among others.

ID: IN10CAPH562 CATEGORY: Pharmaceuticals GEOGRAPHY: Canada AUTHOR: Aryan Patel

Buy Now

Canada Hepatitis A Therapeutics Market Executive Summary

The Canada Hepatitis A Therapeutics Market valued at $58.98 Mn in 2023, projected to reach $68.68 Mn by 2030 with a CAGR of 2.2%.

Hepatitis A is a highly contagious liver infection caused by the Hepatitis A virus (HAV), primarily spread through the fecal-oral route via contaminated food or water. Outbreaks can be sporadic or epidemic, with infection rates higher in areas with poor sanitation. In high-income countries like Canada, infection rates are lower but still pose a risk to high-risk groups such as drug users, men who have sex with men, travelers, and isolated populations. Effective prevention includes improved sanitation, food safety, and vaccination. The Hepatitis A vaccine is recommended for those over six months at increased risk, offering at least 90% protection. Travelers to endemic regions and patients with chronic liver disease are advised immunization in Canada.

Canada is burdened with Hepatitis A infections, with a prevalence rate of 0.68 per 100,000 persons. This has resulted from various factors like the consumption of frozen foods, the high-risk behavior of Canadians, etc. The market is driven by rising prevalence, challenges in hygiene and sanitation, and government initiatives and restrained by stringent regulatory processes, limited treatment options, and limited public funding for hepatitis A vaccination.

Canada Hepatitis A Therapeutics Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Rising Prevalence: Hepatitis A is a nationally notifiable disease in Canada and is reported at a rate of 0.68 per 100,000 persons. The rising prevalence of Hepatitis A in Canada can be attributed to various factors. The increased consumption of frozen foods, such as frozen strawberries, mangoes, and pomegranate arils, has been associated with multiple foodborne Hepatitis A outbreaks. Additionally, high-risk behaviors among Canadians, including practices like oral/anal sex, contribute to the transmission of the virus. Furthermore, the lack of personal hygiene among Canadians serves as a prime cause of Hepatitis A outbreaks. These factors collectively contribute to the rising incidence of Hepatitis A in Canada, thus driving the market.

Lack of personal hygiene and sanitation facilities: The rise in the population of homeless people often faces challenges in maintaining proper personal hygiene due to limited access to sanitation facilities. Factors such as heavy drinking, drug use, and sleeping outdoors are associated with reduced hygiene practices, increasing the risk of Hepatitis A transmission.

Government Initiatives: Government initiatives, including vaccination campaigns and public health programs in Canada, drive the Hepatitis A therapeutics market. Led by the Public Health Agency of Canada (PHAC), these initiatives aim to boost vaccination coverage rates and manage Hepatitis A infections effectively. Provincial and territorial vaccination programs offer routine Hepatitis A vaccination for specific populations or age groups. For example, Quebec provides one dose of the Hepatitis A and B vaccine at 18 months of age, with a booster dose in Grade 4. These efforts have led to a notable increase in vaccination coverage rates, contributing significantly towards driving the market.

Market Restraints

Stringent regulatory processes: Stringent regulatory approval processes and complex intellectual property laws present formidable barriers in Canada's Hepatitis A therapeutics market. These hurdles, characterized by demanding clinical trial requirements and patent disputes, impede the introduction of generic drugs, constraining competition and maintaining elevated prices. Market exclusivity compounds the issue, prolonging the availability of economic alternatives post-patent expiration. Consequently, the high costs associated with regulatory navigation and approval attainment inflate prices. All these factors restrain the market.

Limited Treatment Options: Only one commercially available medication is approved for Hepatitis A treatment in Canada. This constraint limits therapeutic choices for healthcare providers and patients, hindering competition, innovation, and access to alternative therapies, thus restricting market growth.

Limited Public Funding for Hepatitis A Vaccination: The market faces challenges due to limited public funding for Hepatitis A vaccination in Canada. While vaccines are available, publicly funded vaccination is generally targeted toward high-risk groups and routine childhood immunization is only implemented in Quebec. This limited public funding restricts access to vaccination for specific populations, potentially decreasing the demand.

Regulatory Landscape and Reimbursement Scenario

The reimbursement scenario in Canada operates under the Canada Health Act (CHA), ensuring eligible residents have access to publicly funded, medically necessary health services. Hepatitis A (HA) vaccines, recommended for travelers and at-risk individuals, may vary in reimbursement details by province. Like provincial health plans, public payers cover a significant portion of the population, while private payers offer additional coverage options. Pharmaceutical companies play a crucial role in therapeutics development, and Pharmacy Benefit Managers (PBMs) influence coverage decisions and negotiate drug prices.

Regulatory bodies involved in the reimbursement process include Health Canada, which regulates the safety, efficacy, and quality of therapeutic and diagnostic products, and the Health Products and Food Branch (HPFB), which oversees the drug review process and ensures the well-being of Canadians.

Competitive Landscape

Key Players

Here are some of the major key players in the Hepatitis A Therapeutics Market:

F. Hoffmann-La Roche Ltd.
Merck & Co. Inc.
Sanofi
GlaxoSmithKline (GSK)
Takeda
CVS Health Corporation
Zydus Cadila

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Canada Hepatitis A Therapeutics Market Segmentation

By Distribution Channel

Hospital-based pharmacies
Retail pharmacies
Online pharmacies

By Route of Administration

Oral Medications
Intravenous Therapy

By Healthcare Setting

Outpatient Care
Inpatient Care

By Age

Children
Adults
Senior Citizens

Insights10 will provide you with the reports within 10 key parameters which are:

Market Overview
Market Growth Drivers & Restraints
Epidemiology of Disease Type
Market Segmentation
Market Share
Competitive Landscape
Key Company Profiles
Healthcare Policies & Regulatory Framework
Reimbursement Scenario
Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

Establishing market drivers and trends
Analyzing the regulatory landscape to understand future growth
Market Segment based analysis to obtain revenue/volume
Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.